CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma

CMP-001-010 is a Phase 2 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) administered to participants with refractory unresectable or metastatic melanoma.

The primary objective of the study is to determine confirmed objective response with CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma.

The secondary objectives are to:

• To evaluate the safety and tolerability of CMP-001 administered by intratumoral (IT) injection in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma.
• To evaluate the efficacy of CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma.
• To assess the pharmacokinetic (PK) profile of CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma.
• To assess and describe the immunogenicity of CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma.

Study Overview

• Status: Terminated
• Conditions: Melanoma; Metastatic Melanoma; Unresectable Melanoma; Advanced Melanoma
• Intervention / Treatment: Drug: CMP-001; Drug: Nivolumab

Detailed Description

Former Sponsor Checkmate Pharmaceuticals

• Study Type: Interventional
• Enrollment (Actual): 44
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85054
      • Mayo Clinic
  • California
    • Duarte, California, United States, 91010
      • City of Hope National Medical Center, Robert Kang, MD
    • Los Angeles, California, United States, 90095
      • UCLA Hematology-Oncology
    • San Marcos, California, United States, 92069
      • California Cancer Associates for Research & Excellence, Inc.
  • Colorado
    • Denver, Colorado, United States, 80204
      • University of Colorado- Denver
  • Connecticut
    • Hartford, Connecticut, United States, 06106
      • Hartford Healthcare
  • Florida
    • Jacksonville, Florida, United States, 32204
      • GenesisCare USA
    • Orlando, Florida, United States, 32806
      • Orlando Health
    • Weston, Florida, United States, 33331
      • Cleveland Clinic Florida
  • Georgia
    • Athens, Georgia, United States, 30607
      • University Cancer & Blood Center
    • Atlanta, Georgia, United States, 30322
      • Emory University Winship Cancer Institute
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Northwestern University
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • University of Iowa
  • Kentucky
    • Louisville, Kentucky, United States, 40202
      • University of Louisville Health Care
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Massachusetts General Hospital
  • New York
    • New York, New York, United States, 10065
      • Memorial Sloan Kettering Cancer Center
    • New York, New York, United States, 10032
      • Columbia University Herbert Irving Comprehensive Cancer Center
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Duke University Cancer Institute
  • Ohio
    • Columbus, Ohio, United States, 43220
      • The Ohio State University
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73104
      • Stephenson Cancer Center
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19107
      • Thomas Jefferson University
    • Pittsburgh, Pennsylvania, United States, 15232
      • University of Pittsburgh Medical Center
  • Texas
    • Dallas, Texas, United States, 75246
      • Sammons Cancer Center
  • Utah
    • Salt Lake City, Utah, United States, 84112
      • University of Utah- Huntsman Cancer Institute
  • Washington
    • Seattle, Washington, United States, 98109
      • Seattle Cancer Care Alliance

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Subjects enrolled in the study must meet all of the following inclusion criteria to be eligible.

1. Histopathologically-confirmed diagnosis of malignant melanoma that is metastatic or unresectable at Screening.
2. Known BRAF mutation status; if BRAF V600 mutation positive, must have had prior treatment with a local Health Authority approved BRAF inhibitor, with or without mitogen-activated protein kinase inhibitor. Patients with BRAF V600 mutations who refuse a BRAF inhibitor will not be eligible.

3. Refractory to PD-1 blockade either as monotherapy or in combination with other therapies, as defined by the following criteria:

   1. Received treatment with a Food and Drug Administration approved PD-1 blocking antibody for 12 weeks or longer.
   2. Have PD (according to RECIST v1.1) within 12 weeks of the last dose of a PD-1 blocking antibody, either as monotherapy or in combination with other agents.

   Evidence of confirmed PD must be established by investigator assessment at least 4 weeks after the initial date of PD. The second assessment may serve as the Baseline for this study if completed within 30 days before to the start of study treatment. NOTE: in subjects with histologically confirmed recurrence on or after adjuvant PD-1 blocking antibody, confirmatory imaging is not required.

4. Measurable disease, as defined by RECIST v1.1 and all of the following:

   1. At least 1 accessible lesion amenable to repeated IT injection.
   2. One or more measurable lesions at least 1 cm in diameter that are not intended for CMP 001 injection and can be followed as target lesions per RECIST v1.1.
   3. Documented disease progression in any lesion that was previously radiated in order to serve as a target lesion.
5. Able to provide tissue from a core or excisional biopsy (fine needle aspirate is not sufficient). A fresh tissue biopsy (within 90 days before the start of study treatment) is preferred but an archival sample is acceptable if no intervening therapy was received. Note: For tissue sampling details, please refer to the laboratory manual.

6. Adequate organ function based on most recent laboratory values within 3 weeks before first dose of study treatment on Week 1 Day 1 (W1D1):

   1. Bone marrow function:

      • neutrophil count ≥ 1500/mm3
      • platelet count ≥ 100,000/mm3
      • hemoglobin concentration ≥ 9 g/dL
      • white blood cells ≥ 2000/mm3

   2. Liver function:

      • total bilirubin ≤ 1.5 times the upper limit of normal (ULN) with the following exception: patients with Gilbert Disease total serum bilirubin ≤ 3 times ULN
      • aspartate aminotransferase and alanine aminotransferase ≤ 3 times the ULN
   3. Lactate dehydrogenase ≤ 2 times the ULN
   4. Renal function: estimated (Cockcroft-Gault) or measured creatinine clearance ≥ 30 mL/min.

   5. Coagulation:

      • International normalized ratio or prothrombin time (PT) ≤ 1.5 times ULN, unless subject is receiving anticoagulant therapy, as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
      • Activated partial thromboplastin time or PTT ≤ 1.5 times ULN, unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants
7. Age ≥ 18 years at time of consent.
8. Eastern Cooperative Oncology Group Performance Status of 0 to 1 at Screening.
9. Capable of understanding and complying with protocol requirements.
10. Women of childbearing potential must have negative serum pregnancy test before dosing at W1D1 and be willing to use an adequate method of contraception from the time of consent until at least 150 days after last dose of study treatment.
11. Able and willing to provide written informed consent and to follow study instructions. Subjects unable to provide written informed consent on their own behalf will not be eligible for the study.

Exclusion Criteria:

Subjects presenting with any of the following will not qualify for entry into the study:

1. Uveal, acral, or mucosal melanoma.
2. Received radiation therapy (or other nonsystemic therapy) within 2 weeks before first dose of study treatment on W1D1. Patients should have recovered (ie, Grade ≤1 or at baseline) from radiation-related toxicities.
3. Treatment with complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before start of study treatment. Refer to Section 4.4. for prohibited therapies.

4. Received systemic pharmacologic doses of corticosteroids ≥10 mg/day prednisone within 30 days before first dose of study treatment on W1D1.

   1. Subjects who are currently receiving steroids at a prednisone-equivalent dose of ≤ 10 mg/day do not need to discontinue steroids before enrollment.
   2. Replacement doses, topical, ophthalmologic, and inhalational steroids are permitted.
   3. Stress-dose corticosteroids will be required in subjects with adrenal insufficiency
5. History of immune-related AE that required permanent discontinuation of PD-1 blocking antibody.

6. Not fully recovered from AEs (to Grade 1 or less [per CTCAE v5.0], with the exception of persistent adverse events or sequelae, eg, vitiligo, alopecia, hypothyroidism, diabetes mellitus, and adrenal and/or pituitary insufficiency) due to prior treatment.

   NOTE: Subjects previously treated with a CTLA-4-blocking antibody, subjects receiving corticosteroids with daily doses > 5 mg and ≤ 10 mg of prednisone equivalent for 2 weeks, and subjects with clinical symptoms and/or laboratory findings suggesting risk for adrenal insufficiency should undergo diagnostic tests for adrenal insufficiency via local laboratory.

7. Active pneumonitis or history of noninfectious pneumonitis that required steroids.
8. Severe uncontrolled cardiac disease within 6 months of Screening, including but not limited to poorly controlled hypertension, unstable angina, myocardial infarction, congestive heart failure (New York Heart Association Class II or greater), pericarditis within the previous 6 months, cerebrovascular accident, or implanted or continuous use of a pacemaker or defibrillator.
9. Known history of immunodeficiency.
10. Known additional malignancy that is progressing or required active treatment within the past 3 years. Exceptions include cancers that have undergone potentially curative therapy, eg, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, localized prostate cancer with prostate-specific antigen level below 4.0 ng/mL, in situ cervical cancer on biopsy or a squamous intraepithelial lesion on Papanicolaou smear, and thyroid cancer (except anaplastic), in situ breast cancer, and adjuvant hormonal therapy for breast cancer > 3 years from curative-intent surgical resection.
11. Active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy is not considered a form of systemic treatment.
12. Untreated, symptomatic, or enlarging central nervous system metastases or carcinomatous meningitis (including leptomeningeal metastases from solid tumors).
13. Prior allogenic tissue/solid organ transplant.
14. Active infection requiring systemic therapy.
15. Known or suspected active infection with severe acute respiratory syndrome coronavirus 2 virus.
16. Known or suspected active infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus (testing is not required unless suspected).
17. Received a live virus/attenuated vaccination within 30 days before first dose of study treatment on W1D1.
18. Received blood products (including platelets or red blood cells) or colony stimulating factors (including granulocyte colony stimulating factor, granulocyte/macrophage colony stimulating factor, or recombinant erythropoietin) within 30 days before the start of Screening.
19. History of allergy or hypersensitivity to nivolumab and/or any of its excipients.
20. Any concurrent uncontrolled illness, including mental illness or substance abuse, which in the opinion of the Investigator would make the subject unable to cooperate or participate in the study.
21. Participation in another clinical study of an investigational anticancer therapy or device within 30 days before first dose of study treatment on W1D1. Participation in the follow-up phase (receiving no study treatment) of a prior study is allowed.
22. Requires prohibited treatment (ie, non-protocol specified anticancer pharmacotherapy, surgery, or radiotherapy) for treatment of malignant tumor.
23. Has a life expectancy of less than 3 months and/or has rapidly progressing disease (eg, tumor bleeding, uncontrolled tumor pain) in the opinion of the treating Investigator.
24. Received previous CMP-001 treatment.
25. Pregnant or breastfeeding or expecting to conceive or donate eggs within the projected duration of the study, from the time of consent until at least 150 days after last dose of study treatment for women.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CMP-001 and Nivolumab; All enrolled subjects will receive CMP-001 IT and nivolumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.	Drug: CMP-001; Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).; Other Names: vidutolimod; Drug: Nivolumab; Nivolumab 360 mg IV is administered Q3W.; Other Names: OPDIVO

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Confirmed Objective Response Rate (ORR) by Blinded Independent Central Review (BICR)	ORR, defined as the percentage of participants who have confirmed best overall response (BOR) of complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)	Up to approximately 24 months (107 weeks)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Any Serious TEAE, and Any TEAE Leading to Discontinuation or Death	Number of participants with any treatment-emergent adverse event (TEAE), any serious TEAE, and any TEAE leading to discontinuation or death reported.	Up to approximately 24 months (107 weeks)
Severity of TEAEs as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)	Number of participants per NCI CTCAE version 5.0 Adverse Event Grade reported: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2 Moderate; minimal, local, or non-invasive intervention indicated; limiting age-appropriate instrumental activities of daily living Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limited self-care activities of daily living Grade 4 Life-threatening consequences: urgent intervention indicated Grade 5 Death related to adverse event	Up to approximately 24 months (107 weeks)
Time to Response (TTR) by BICR	TTR, defined as the time from the first dose date of the study treatment to the first time when criteria are first met for CR or PR, whichever occurred first, per RECIST v1.1 by BICR.	Up to approximately 28 months (122 weeks)
Time to Response (TTR) by Investigator	TTR, defined as the time from the first dose date of the study treatment to the first time when criteria are first met for CR or PR, whichever occurred first, per RECIST v1.1 by Investigator.	Up to approximately 28 months (122 weeks)
Duration of Response (DOR) by BICR	DOR, defined as time from the date of first documented response (CR or PR) to the date of documented progressive disease (PD), based on RECIST v1.1 by BICR.	Up to approximately 28 months (122 weeks)
Duration of Response (DOR) by Investigator	DOR, defined as time from the date of first documented response (CR or PR) to the date of documented progressive disease (PD), based on RECIST v1.1 by Investigator.	Up to approximately 28 months (122 weeks)
Confirmed ORR in Non-injected Target Lesions by Investigator	Confirmed ORR, defined as the percentage of participants in the analysis set who had confirmed BOR of CR or PR based on RECIST v1.1 as assessed by Investigator.	Up to approximately 24 months (107 weeks)
Progression-free Survival (PFS) by BICR	PFS, defined as time from date of first dose of study treatment to date of documented PD based on RECIST v1.1 by BICR or death, whichever occurred first.	Up to approximately 31 months (135 weeks)
Progression-free Survival (PFS) by Investigator	PFS, defined as time from date of first dose of study treatment to date of documented PD based on RECIST v1.1 by Investigator or death, whichever occurred first.	Up to approximately 31 months (135 weeks)
Overall Survival (OS) by Investigator	OS, defined as the time from the first dose date of the study treatment to the date of death from any cause.	Up to approximately 32 months (139 weeks)
Immune Objective Response Rate (iORR) by Investigator	iORR, defined as the percentage of participants with an immune best overall response (iBOR) of confirmed immune complete response (iCR) or confirmed immune partial response (iPR) based on immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST) by Investigator assessment.	Up to approximately 24 months (107 weeks)
Immune Duration of Response (iDOR) by Investigator	iDOR, defined as the time from the date of the first immune response (iCR or iPR) to the date of immune confirmed progressive disease (iCPD) by Investigator assessment.	Up to approximately 28 months (122 weeks)
Immune Progression-free Survival (iPFS) by Investigator	iPFS, defined as the time from the first dose date of the study treatment to date of immune confirmed progressive disease (iCPD) per iRECIST by Investigator assessment or death, whichever occurred first.	Up to 9 months (approximately 39 weeks)
Maximum Observed Serum Concentration	Assess the pharmacokinetic (PK) profile for maximum observed serum concentration.	From first dose of drug (Week 1 Day 1) until 30 days after the last drug injection (until a reason for treatment discontinuation occurs)
Area Under the Serum Concentration-Time Curve From Time Zero to the Last Quantifiable Time Point	Assess the PK profile for area under the serum concentration-time curve from time zero to the last quantifiable time point.	From first dose of drug (Week 1 Day 1) until 30 days after the last drug injection (until a reason for treatment discontinuation occurs)
Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity	Assess the PK profile for area under the serum concentration-time curve from time zero extrapolated to infinity.	From first dose of drug (Week 1 Day 1) until 30 days after the last drug injection (until a reason for treatment discontinuation occurs)
Terminal Elimination Half-Life	Assess the PK profile for terminal elimination half-life.	From first dose of drug (Week 1 Day 1) until 30 days after the last drug injection (until a reason for treatment discontinuation occurs)
Number of Participants With Immunogenicity as Measured by Anti-Qbeta Antibodies (ADA)	Development of anti-Qbeta antibodies in participants with refractory unresectable or metastatic melanoma.	Up to approximately 24 months (107 weeks)

Collaborators and Investigators

• Sponsor: Regeneron Pharmaceuticals
• Collaborators: Bristol-Myers Squibb
• Investigators: Study Director: Clinical Trial Management, Regeneron Pharmaceuticals

Publications and helpful links

Helpful Links

• A Plain Language Summary is available on TrialSummaries.com

Study record dates

Study Major Dates

• Study Start (Actual): March 11, 2021
• Primary Completion (Actual): February 5, 2024
• Study Completion (Actual): February 5, 2024

Study Registration Dates

• First Submitted: December 10, 2020
• First Submitted That Met QC Criteria: January 5, 2021
• First Posted (Actual): January 6, 2021

Study Record Updates

• Last Update Posted (Actual): June 11, 2025
• Last Update Submitted That Met QC Criteria: June 9, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Skin Diseases; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroendocrine Tumors; Nevi and Melanomas; Skin Neoplasms; Melanoma; Antineoplastic Agents, Immunological; Immune Checkpoint Inhibitors; Antineoplastic Agents; Molecular Mechanisms of Pharmacological Action; Nivolumab
• Other Study ID Numbers: CMP-001-010

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
• IPD Sharing Time Frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
• IPD Sharing Access Criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No